Arca
Skip to content

PARP2: Poly [ADP-ribose] polymerase 2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Poly-ADP-ribosyltransferase that mediates poly-ADP- ribosylation of proteins and plays a key role in DNA repair.

  • Drugs that act on it: 5
  • With a US drug page: 2
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
NiraparibApprovedPoly [ADP-ribose] polymerase 2 inhibitorInhibitor—
TalazoparibApprovedPoly [ADP-ribose] polymerase 2 inhibitorInhibitor—
2X-121—Poly [ADP-ribose] polymerase 2 inhibitorInhibitor—
Pamiparib—Poly [ADP-ribose] polymerase 2 inhibitorInhibitor—
Senaparib—Poly [ADP-ribose] polymerase 2 inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Neoplasm
0.57
Ovarian carcinoma
0.55
Primary peritoneal carcinoma
0.52
Breast neoplasm
0.51
Ovarian neoplasm
0.50
Peritoneum cancer
0.50
Pancreatic neoplasm
0.49
Fallopian tube carcinoma
0.49

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
PARP2

Drugs and mechanisms are from ChEMBL CHEMBL5366 (CC BY-SA 3.0). Gene name, function (UniProt Q9UGN5, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.